Pfizer Inc.
Rank #310ValuePFE · NYSE · Healthcare
Pfizer Inc. (PFE) — Rank #310 by gross profitability (GP/assets 0.23) · ROE 9.1% · Piotroski F-Score 5 / 9.
As-of 2026-09-15 · CIK 0000078003 · all metrics point-in-time as of the filing date.
About
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Show moreShow less
It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc.
was founded in 1849 and is headquartered in New York, New York.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- pfizer.com
Price History
Company Snapshot
P/E and dividend yield are the primary valuation lenses for mature businesses.
Market Cap
$156.63B
P/E (annual)
20.2
P/S (annual)
2.5
P/B
1.8
P/OCF (annual)
13.4
Shareholder Yield
-0.2%
Employees
75,000
Industry
Drug Manufacturers - General
Exchange
NYSE
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passTerry Smith quality gate
Passes 2/5 Terry Smith thresholds3 of 5 thresholds not computable from filed data.
What Growth Is Priced In
Implied revenue growth (10Y)
5.7%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Dilution drag: 0.2% — per-share value needs a total required return of 6.0% once share-count change is priced in.
vs. own 6-year median revenue growth: 15.1%
within its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
1.5%
r = 10% (base)
5.7%
r = 12%
9.4%
Net debt / market cap: 33.6%— material leverage inflates the implied growth read.
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / E
Price / diluted EPS
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
P / FCF
Price / free cash flow per share
Dividend yield and payout ratio are the primary reads at this stage (trailing P/E — see valuation above).
Profitability
Gross profitability (GP / assets)
0.23
Primary signal (Novy-Marx).
7th of 9 SIC 2834 peers
Return on equity
9.1%
Gross margin
74.3%
6th of 9 SIC 2834 peers
Revenue growth (YoY)
-1.6%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
-14.8%
Revenue CAGR (5Y)
8.5%
Earnings CAGR (3Y)
-37.2%
FCF CAGR (3Y)
-29.6%
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
1.35
8th of 9 SIC 2834 peers (best = lowest)
Current ratio
1.27×
9th of 9 SIC 2834 peers
Quick ratio
0.64×
Net cash
-$52.82B
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$9.07B
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
0.17
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
1.3%
Stock-based comp intensity.
Piotroski F-Score
F-Score
5 / 9
Fundamental-strength score (0-9).